Pre‑exposure Prophylaxis Awareness and Endorsement Among Adolescents and Young Adults in Tanzania: Insights from the 2022 Demographic and Health Survey

Overview

Journal Ann Glob Health

Publisher Ubiquity Press

Date 2025 Feb 3

PMID 39896105

Authors

Alpha Johnson Kapola

Rahma Musoke

Glenda Marie Manayon

Hassan Fredrick Fussi

Hafidha Mhando Bakari

Haji Mbwana Ally

Swalehe Mustafa Salim

Zuhura Mbwana Ally

Lynn Moshi

Mariam Salim Mbwana

Habib Omari Ramadhani

Affiliations

Soon will be listed here.

Abstract

Pre‑exposure prophylaxis (PrEP) is an effective measure for preventing human immunodeficiency virus (HIV) infection among people at risk, including adolescents and young adults (AYA). This study evaluates the prevalence of PrEP awareness and endorsement, as well as the factors associated with these outcomes, using data from the 2022 Tanzania Demographic and Health Survey. The analysis included participants aged 15-24 years. Participants were asked whether they had ever heard of daily medication to prevent HIV (PrEP) and whether they approved of daily PrEP use. Demographic characteristics and HIV testing information were also collected. Logistic regression models were used to assess factors associated with PrEP awareness and endorsement, and the weighted prevalence of these outcomes was calculated. A total of 8,268 respondents aged 15-24 years were evaluated, of whom 5,852 (70.9%) were female. Overall, the prevalence of PrEP awareness and endorsement was 6.9% (95% confidence interval [CI] 6.2-7.7) and 5.7% (95% CI 5.1-6.4), respectively. Female respondents (adjusted odds ratio [aOR] = 0.69; 95% CI 0.51-0.91) and rural residents (aOR = 0.78; 95% CI 0.61-1.00) had lower odds of PrEP awareness compared with male respondents and urban residents, respectively. Previously, HIV testing and receiving test results (aOR = 2.00; 95% CI 1.50-2.66) and an age of 20-24 years versus 15-19 years (aOR = 1.54; 95% CI 1.20-1.96) were associated with increased odds of PrEP awareness. The odds of AYA endorsement of PrEP were higher among those aged 20-24 years versus 15-19 years (aOR = 1.39; 95% CI 1.07-1.83) and those who previously tested for HIV and received results (aOR = 1.97; 95% CI 1.43-2.72), but lower among female respondents (aOR = 0.66; 95% CI 0.49-0.88). PrEP awareness and endorsement among AYA in Tanzania were low, with nearly 7 in 100 aware of PrEP and 6 in 100 approving of its use. Targeted interventions focused on adolescents, females, and rural communities are needed to increase PrEP awareness and usage to achieve the Joint United Nations Programme on HIV/Acquired Immune Deficiency Syndrome (AIDS) (UNAIDS) 95-95-95 goals for HIV epidemic control.

References

Ferrand R, Lowe S, Whande B, Munaiwa L, Langhaug L, Cowan F . Survey of children accessing HIV services in a high prevalence setting: time for adolescents to count?. Bull World Health Organ. 2010; 88(6):428-34. PMC: 2878143. DOI: 10.2471/BLT.09.066126. View

Kabaghe A, Singano V, Payne D, Maida A, Nyirenda R, Mirkovic K . Awareness of and willingness to use oral pre-exposure prophylaxis (PrEP) for HIV prevention among sexually active adults in Malawi: results from the 2020 Malawi population-based HIV impact assessment. BMC Infect Dis. 2023; 23(1):712. PMC: 10589952. DOI: 10.1186/s12879-023-08683-1. View

Young L, Schumm P, Alon L, Bouris A, Ferreira M, Hill B . PrEP Chicago: A randomized controlled peer change agent intervention to promote the adoption of pre-exposure prophylaxis for HIV prevention among young Black men who have sex with men. Clin Trials. 2017; 15(1):44-52. PMC: 5799010. DOI: 10.1177/1740774517730012. View

Celum C, Delany-Moretlwe S, Baeten J, van der Straten A, Hosek S, Bukusi E . HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019; 22 Suppl 4:e25298. PMC: 6643076. DOI: 10.1002/jia2.25298. View

Ajayi A, Mudefi E, Yusuf M, Adeniyi O, Rala N, Ter Goon D . Low awareness and use of pre-exposure prophylaxis among adolescents and young adults in high HIV and sexual violence prevalence settings. Medicine (Baltimore). 2019; 98(43):e17716. PMC: 6824740. DOI: 10.1097/MD.0000000000017716. View

Martin V, Tesha N, Sunguya B . Uptake of Oral HIV Pre-Exposure Prophylaxis (PrEP) and Associated Factors among Female Sex Workers in Tanga, Tanzania. Viruses. 2023; 15(10). PMC: 10611315. DOI: 10.3390/v15102125. View

Jourdain H, Billioti de Gage S, Desplas D, Dray-Spira R . Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study. Lancet Public Health. 2022; 7(6):e529-e536. DOI: 10.1016/S2468-2667(22)00106-2. View

ORourke S, Hartmann M, Myers L, Lawrence N, Gill K, Morton J . The PrEP Journey: Understanding How Internal Drivers and External Circumstances Impact The PrEP Trajectory of Adolescent Girls and Young Women in Cape Town, South Africa. AIDS Behav. 2021; 25(7):2154-2165. PMC: 8651257. DOI: 10.1007/s10461-020-03145-0. View

Owens C . HIV pre-exposure prophylaxis awareness, practices, and comfort among urban and rural family medicine physicians. J Rural Health. 2022; 39(2):469-476. DOI: 10.1111/jrh.12723. View

10.

Kampamba M, Nelumbu N, Hikaambo C, Mudenda S, Hangoma J, Kunda M . Awareness and willingness to use pre-exposure prophylaxis among the University of Zambia students: A cross-sectional study. Health Sci Rep. 2024; 7(9):e70060. PMC: 11386235. DOI: 10.1002/hsr2.70060. View

11.

Ramadhani H, Crowell T, Nowak R, Adebajo S, Kayode B, Ononaku U . Determinants of Preexposure Prophylaxis Cascade Among Sexual and Gender Minorities in Nigeria. Sex Transm Dis. 2023; 50(9):559-566. PMC: 10527664. DOI: 10.1097/OLQ.0000000000001841. View

12.

Rodriguez A, Horvath K, Dowshen N, Voss R, Warus J, Jacobs M . Awareness and utilization of pre-exposure prophylaxis and HIV prevention services among transgender and non-binary adolescent and young adults. Front Reprod Health. 2024; 5:1150370. PMC: 10839107. DOI: 10.3389/frph.2023.1150370. View

13.

Faini D, Munseri P, Sandstrom E, Hanson C, Bakari M . Awareness, Willingness and Use of HIV Pre-Exposure Prophylaxis Among Female Sex Workers Living in Dar-es-Salaam, Tanzania. AIDS Behav. 2022; 27(1):335-343. PMC: 9852168. DOI: 10.1007/s10461-022-03769-4. View

14.

Walters S, Frank D, Van Ham B, Jaiswal J, Muncan B, Earnshaw V . PrEP Care Continuum Engagement Among Persons Who Inject Drugs: Rural and Urban Differences in Stigma and Social Infrastructure. AIDS Behav. 2021; 26(4):1308-1320. PMC: 8501360. DOI: 10.1007/s10461-021-03488-2. View

15.

Kibengo F, Ruzagira E, Katende D, Bwanika A, Bahemuka U, Haberer J . Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS One. 2013; 8(9):e74314. PMC: 3784443. DOI: 10.1371/journal.pone.0074314. View

16.

Currie D, West C, Patel H, Favaloro J, Asiimwe F, Ndagije F . Risk Factors for Recent HIV Infections among Adults in 14 Countries in Africa Identified by Population-Based HIV Impact Assessment Surveys, 2015-2019. Emerg Infect Dis. 2023; 29(11):2325-2334. PMC: 10617335. DOI: 10.3201/eid2911.230703. View